Navigation Links
Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis

EVRY, France, April 04, 2007 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company specialized in ophthalmology, announces today positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC). In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability to Vekacia(R) was excellent.

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In March 2006, Novagali received European Medicines Agency (EMEA) orphan drug designation for Vekacia(R) in the treatment of VKC.

The study was conducted by key experts and opinion leaders in the field of ocular allergy throughout Europe and Mediterranean area and lead by Pr David Ben Ezra, Hadassah Hebrew University Hospital, Jerusalem, who first reported on the use and potential efficacy of Cyclosporine A for the treatment of VKC.

Vekacia(R) is a topical Cyclosporine A cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy. This proprietary ophthalmic emulsion of Cyclosporine A will be the first therapeutic product dedicated to treatment of such a severe ocular condition.

"We achieved a major corporate milestone completing our first phase III clinical trial" declares Jerome Martinez, President & CEO of Novagali, "I am very enthusiastic about the confirmation of the high potential of Novasorb(R) cationic emulsion technology through the development of Vekacia(R) and its successful use in VKC. It is very encouraging for the other ongoing projects".

"It is a great satisfaction to b e able to anticipate providing a product addressing such an unmet therapeutic need in a paediatric population" says Florence Binlich Novagali's Medical Director who adds "we are also impressed by the high level of motivation and enthusiasm of the experts who participated in the trial".

"As practicing clinicians, we are very pleased to observe that Vekacia(R) brought significant benefits even in severe forms of the disease" declared Pr Ben Ezra, study lead investigator "It can confidently be said that now, the treating ophthalmologists may have, finally, a new and efficient tool for the management of VKC".

Based upon the results of the study, Novagali plans to file European Marketing Authorization mid-2007.

About Novagali Pharma: http://www.novagali.com

Novagali Pharma SA is an emerging ophthalmic pharmaceutical company based in the Genopole biocluster in Evry, France, that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 6 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis; Cationorm(R), a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, the firm has raised a total amount of Euro 44 million in 3 series of financing.

CONTACT: Press Contact: Genevieve Garrigos, +33(0)6-82-85-58-99, genevieve.garrigos@novagali.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... AMSTERDAM , Feb. 17, ... connected health offerings at the  ...  (NYSE: PHG,AEX: PHIA), a global ... a broad range of population ... personal health solutions, fully integrated in a ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & ... **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... (CA) and preventive action (PA)? , The methods share techniques and tools but ...
(Date:2/17/2017)... ... , ... Program will serve more than 5,000 kids in ... Foundation announced today that they have awarded nine grants to expand the Foundation’s ... mentoring program, teaches kids the fundamentals of soccer while striving to help them ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national ... was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... made notable contributions to the staffing industry over the last twelve months. Industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows ... of research, development and clinical trials, the founder of Chigurupati Technologies has invented ... of FDA approved ingredients that when infused into alcohol, protect the consumer’s liver ...
Breaking Medicine News(10 mins):